

NATURAL HEALTH PRODUCT

l-EPHEDRINE

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.

Note

- ▶ Text in parentheses is additional optional information which can be included on the PLA and product label at the applicant's discretion.
- ▶ The solidus (/) indicates that the terms and/or statements are synonymous. Either term or statement may be selected by the applicant.

Compliance with Precursor Control Regulations:

The *Precursor Control Regulations* (PCR) (JC 2018) allows Canada to fulfill its international obligations with respect to the *United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988*, and provides a framework for the regulation of activities involving precursor chemicals which can be used in the production of illicit drugs and substances. Under the PCR, regulated chemicals are grouped into two classes: Class A and Class B. For Class A precursors such as ephedrine and/or products containing them, persons wishing to be involved in activities such as importation, exportation, production, packaging, selling, and/or providing must first obtain a licence.

Further information regarding compliance with the PCR, including application forms and guidance documents pertaining to the application for a Class A precursor licence, is available at <http://www.healthcanada.gc.ca/precursors>.

Date July 31, 2018

Proper name(s), Common name(s), Source material(s)

Table 1. Proper name(s), Common name(s), Source material(s)

Proper name(s)	Common name(s)	Source material(s)
		Common name(s)
<ul style="list-style-type: none"> ▶ (1R,2S)-2-Methylamino-1-phenylpropan-1-ol ▶ (alphaR)-alpha-[(1S)-1-(Methylamino)ethyl]-benzenemethanol ▶ [R-(R*,S*)]-alpha-[1-(Methylamino)ethyl]-benzenemethanol ▶ <i>l</i>-Ephedrine 	<ul style="list-style-type: none"> ▶ <i>l</i>-Ephedrine ▶ Ephedrine 	<ul style="list-style-type: none"> ▶ <i>l</i>-Ephedrine ▶ <i>l</i>-Ephedrine hydrochloride ▶ <i>l</i>-Ephedrine sulfate

References: Proper names: NLM 2018, O'Neil et al. 2009, USP32 2009; Common names: NLM 2018, O'Neil et al. 2009, USP32 2009; Source materials: NLM 2018, O'Neil et al. 2009.



Route of administration

Oral

Dosage form(s)

This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document.

Acceptable dosage forms for the age category listed in this monograph and specified route of administration are indicated in the Compendium of Monographs Guidance Document.

Use(s) or Purpose(s)

Used as a decongestant/to relieve nasal congestion (due to hay fever/allergic rhinitis/allergies/ sinusitis/the common cold/flu) (Mills and Bone 2005; Hoffman 2003; Williamson 2003; Blumenthal et al. 2000; BHP 1983),

Dose(s)

Subpopulation(s)

Adolescents 12 to 17 years and adults 18 years and older

Quantity(ies)

8-32 milligrams *l*-Ephedrine per day; Not to exceed 8 milligrams per single dose (HC 2007; US FDA 2004; HC 2003; Pickup et al. 1976).

Direction(s) for use

No statement required.

Duration(s) of use

Consult a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 7 days (Mills and Bone 2005; US FDA 2004; Blumenthal et al. 2000).



Risk information

Caution(s) and warning(s)

- ▶ Keep out of reach of children
- ▶ Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- ▶ Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding (Hackman et al. 2006; Kuczkowski 2006; Mills and Bone 2005; Coffey et al. 2004; Greenway et al. 2004; Haller et al. 2004; Hoffman 2003; Boozer et al. 2002; Boozer et al. 2001; Brinker 2001; Kalman et al. 2000).
- ▶ Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking medication and/or natural health products for allergy symptoms, asthma, cough/cold or weight control (Hackman et al. 2006; Mills and Bone 2005; Naik and Freudenberger 2004; Boozer et al. 2002; Boozer et al. 2001).
- ▶ Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking other products containing caffeine, ephedrine, phenylpropanolamine or pseudoephedrine (Brinker 2018; Hackman et al. 2006; Mills and Bone 2005; Naik and Freudenberger 2004; Boozer et al. 2002; Brinker 2001; Haller and Benowitz 2000; Kalman et al. 2000).
- ▶ Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you have cardiovascular disease, diabetes, difficulty in urination due to prostate enlargement, glaucoma, thyroid problems, seizure disorders or a pre-existing psychiatric condition (Hackman et al. 2006; Mills and Bone 2005; Bensky et al. 2004; Coffey et al. 2004; Greenway et al. 2004; Haller et al. 2004; Hioki et al. 2004; Hoffman 2003; Williamson 2003; Boozer et al. 2002; Boozer et al. 2001; Brinker 2001; Blumenthal et al. 2000; Kalman et al. 2000; BHP 1983).

Contraindication(s)

Do not use this product if you are taking, or have taken monoamine oxidase inhibitors in the past two weeks (Brinker 2018; Greenway et al. 2004; Hoffman 2003; Brinker 2001; Blumenthal et al. 2000; Kalman et al. 2000; Dingemans et al. 1996; Dawson et al. 1995; Elis et al. 1967).

Known adverse reaction(s)

Stop use in case of restlessness, irritability, dizziness, tremor, severe headache, insomnia, loss of appetite, nausea, rapid heartbeat, shortness of breath and/or disturbance of urination (Mills and Bone 2005; Bensky et al. 2004; Mehendale et al. 2004; Shekelle et al. 2003; Boozer et al. 2001; Blumenthal et al. 2000; McGuffin et al. 1997; Astrup et al. 1992).



Non-medicinal ingredients

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

Storage conditions

Store protected from light and moisture (BP 2009; USP 32 2009; Ph. Eur. 2007).

Specifications

- ▶ The finished product specifications must be established in accordance with the requirements described in the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide.
- ▶ The medicinal ingredient must comply with the specifications outlined in the NHPID.

References cited

Astrup, A., Buemann, B., Christensen, N. J., Toubro, S., Thorbek, G., Victor, O. J., Quaade, F. 1992. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. *Metabolism* 41(7):686-688.

Bensky D, Clavey S, Stoger E, Gamble A. 2004. *Chinese Herbal Medicine: Materia Medica*, 3RD Edition. Seattle (WA): Eastland Press.

BHP 1983: British Herbal Medicine Association (BHMA) Scientific Committee. 1983. *British Herbal Pharmacopoeia* 1983. Bournemouth (GB): British Herbal Medicine Association.

Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. *Herbal Medicine: Expanded Commission E Monographs*. Boston (MA): Integrative Medicine Communications.

Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, Strauss R, Meredith T. 2002. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. *International Journal of Obesity and Related Metabolic Disorders* 26(5):593-604.

Boozer CN, Nasser JA, Heymsfield SB, Wang V, Solomon JL. 2001. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. *International Journal of Obesity & Related Metabolic Disorders* 25:316-324.

BP 2009: British Pharmacopoeia Commission. 2008. *British Pharmacopoeia* 2009, Volume 1. London (GB): The Stationary Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA).



Brinker F. 2001. Herb Contraindications and Drug Interactions, Third Edition. Sandy (OR): Eclectic Medical Publications.

Brinker F. 2018. Online Updates and Additions to Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. [Accessed 2018 June 1]. Available from: <https://www.eclecticherb.com/herb-contraindications-drug-interactions/>

Coffey CS, Steiner D, Baker BA, Allison DB. 2004. A randomized double-blind placebocontrolled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. *International Journal of Obesity & Related Metabolic Disorders* 28(11):1411-1419.

Dawson JK, Earnshaw SM, Graham CS. 1995. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. *Journal of Accident and Emergency Medicine* 12:4951.

Dingemans J, Guentert T, Gieschke R, Stabl M. 1996. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase a-inhibitor moclobemide. *Journal of Cardiovascular Pharmacology* 28(6):856-861.

Elis J, Laurence DR, Mattie H, Prichard BNC. 1967. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. *British Medical Journal* 2:75-78.

Greenway FJ, de Jonge L, Blanchard D, Frisard M, Smith, SR. 2004. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. *Obesity Research* 12(7):1152-1157.

Hackman RM, Havel PJ, Schwartz HJ, Rutledge JC, Watnik MR, Noceti EM, Stohs SJ, Stern JS, Keen CL. 2006. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. *International Journal of Obesity* 30:1545-1556.

Haller CA, Benowitz NL. 2000. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. *The New England Journal of Medicine* 343(25):1833-1838.

Haller CA, Jacob P 3rd, Benowitz NL. 2004. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. *Clinical Pharmacology and Therapeutics* 75(4):259-273.

HC 2003: Health Canada reminds Canadian of the dangers of Ephedra/ephedrine products. [Accessed 2018 June 1]. Available from: <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/13279a-eng.php>

HC 2007: Natural Health Products Compliance Guide. Natural Health Products Directorate (NHPD). Ottawa (ON): Minister of Health. [Accessed 2018 June 1]. Available from: http://fitomedicina.org/old/archivos/canada___legislacion_productos_naturales_2.pdf

Hioki C, Yoshimoto K, Yoshida T. 2004. Efficacy of Bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance. *Clinical and Experimental Pharmacology and Physiology* 31:614-619.

Hoffman D. 2003. *Medical Herbalism: The Science and Practice of Herbal Medicine*. Rochester (VT): Healing Arts Press.

JC 2018: Justice Canada. 2018. Precursor Control Regulations. Part 1 – Class A Precursors [online]. Ottawa (ON) Department of Justice Canada. [Accessed 2018 June 1]. Available from: <http://laws-lois.justice.gc.ca/eng/regulations/SOR-2002-359/index.html>

Kalman D, Colker C, Shi O, and Swain M. 2000. Effects of a weight-loss aid in healthy overweight adults: double-blind, placebo-controlled clinical trial. *Current Therapeutic Research* 61(4):199-205.

Kuczkowski KM. 2006. Ephedrine containing oral nutritional supplements in a pregnant athlete: is it worth the risk? *Acta Obstetrica et gynecologica Scandinavica* 85(2):247-248.

McGuffin M, Hobbs C, Upton R, Goldberg A, editors. 1997. *American Herbal Products Association's Botanical Safety Handbook*. Boca Raton (FL): CRC Press.

Mehendale SR, Bauer BA, Yuan C. 2004. Ephedra-containing dietary supplements in the US versus ephedra as a Chinese medicine. *The American Journal of Chinese Medicine* 32(1):1-10.

Mills S, Bone K. 2005. *The Essential Guide to Herbal Safety*. St. Louis (MO): Elsevier Churchill Livingstone.

Naik SJ, Freudenberger RS. 2004. Ephedra-associated cardiomyopathy. *The Annals of Pharmacotherapy* 38:400-403.

NLM 2018: United States National Library of Medicine. ChemIDplus Advanced [online]. Search terms: Pseudoephedrine, Pseudoephedrine Hydrochloride, Pseudoephedrine Sulfate. Bethesda (MD): Specialized Information Services, United States National Library of Medicine, National Institutes of Health, United States Department of Health & Human Services. [Accessed 2018 June 1]. Available from: <https://chem.nlm.nih.gov/chemidplus/name/ephedrine%20l-form>

O'Neil, Maryadele J. 2006. *The Merck Index: an Encyclopedia of Chemicals, Drugs, and Biologicals*. Merck, and Co., Inc. Whitehouse Station, NJ.

Ph. Eur. 2007: European Pharmacopoeia Commission. 2007. *European Pharmacopoeia*, 6th edition. Strasbourg (FR): Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM).



Pickup ME, May Ca, Ssendagire R, Paterson JW. 1976. The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. *British Journal of Clinical Pharmacology* 3:123-134.

Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J. 2003. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. *Journal of the American Medical Association* 289(12):1537-1545.

US FDA 2004: United States Food and Drug Administration. Final Rules Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk; Final Rule [online]. *Federal Register*, Volume 69, Number 28, February 11, 2004, Rules and Regulations, Docket Number 1995N-0304. Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2018 June 1]. Available from: <https://www.federalregister.gov/documents/2004/02/11/04-2912/final-rule-declaring-dietary-supplements-containing-ephedrine-alkaloids-adulterated-because-they>

USP 32 2009: United States Pharmacopeial Convention. 2009. *United States Pharmacopeia and the National Formulary (USP 32 - NF 27)*. Rockville (MD): The United States Pharmacopeial Convention.

Williamson EM. 2003. *Potter's Herbal Cyclopaedia: The Authoritative Reference work on Plants with a Known Medical Use*. Saffron Walden (GB): The C.W. Daniel Company Limited.

References reviewed

Aaronson AL, Ehrlich NJ, Frankel DB, Gutman AA, Aaronson DW. 1968. Effective oral nasal decongestion: A double-blind crossover analysis. *Annals of Allergy* 26(3):145-150.

Bent S, Tiedt TN, Odden MC, Shlipak, MG. 2003. The relative safety of ephedra compared with other herbal products. *Annals of Internal Medicine* 138: 468-471.

Bitsko RH, Reefhuis J, Louik C, Werler M, Feldkamp ML, Waller DK, Frias J, Honein MA. 2008. Periconceptional use of weight loss products including ephedra and the association with birth defects. *Birth Defects Research Part A: Clinical and Molecular Teratology* 82(8):553-562.

Burke LM. 2000. Positive Drug Tests from Supplements. *Sportscience* 4(3):1-5.

CRN 2000: Council for Responsible Nutrition. 2000. Safety assessment and determination of a Tolerable Upper Limit for Ephedra. [online] Mississauga (ON): Cantox Health Sciences International. [Accessed 2009 November 23]. Available from: <http://www.crnusa.org/pdfs/Cantoxreport.doc>



- Cui J, Zhou T. 1991. Analysis of alkaloids in Chinese ephedra species by gas chromatographic methods. *Phytochemical Analysis* 2:116-119.
- Doyle H. 1996. Herbal stimulant containing ephedrine has also caused psychosis. *British Medical Journal* 313:756.
- Drew CD, Knight GT, Hughes DT, Bush M. 1978. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. *British Journal of Clinical Pharmacology* 6(3):221-225.
- Farel RM, Fanta CH. 2009. Drug therapy for asthma. *New England Journal of Medicine* 360(24):2578-2579.
- Glidden RS, DiBona FJ. 1977. Urinary retention associated with ephedrine. *The Journal of Pediatrics* 90(6):1013-1014.
- Grieve M. 1971. *A Modern Herbal, Volume 1*. New York (NY): Dover Publications; [Reprint of 1931 Harcourt, Brace & Company publication].
- Gurley BJ, Gardner SF, White LM, Wang PL. 1998. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing *Ephedra sinica* (ma huang). *Therapeutic Drug Monitoring* 20(4):439-445.
- HC 1996a: TPD/NHPD Category IV Labelling Standard, Ephedra [online]. Ottawa (ON): Therapeutic Products Directorate, Health Canada.
- HC 1996b: TPD/NHPD Category IV Labelling Standard, Ephedrine/Pseudoephedrine [online]. Ottawa (ON): Therapeutic Products Directorate, Health Canada.
- HC 2006: A Summary of NHP/DRUG Classification of TPD Category IV Labelling Standards Ingredients. Natural Health Products Directorate, Health Canada. [Accessed 2009 December 23]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licenprod/monograph/list_mono4-eng.php
- HC 2009: First Nations, Inuit & Aboriginal Health. Drug Benefit List 04:00 Antihistamine Drugs. [Accessed 2009 December 23]. Available from: <http://www.hc-sc.gc.ca/fniah-spnia/nihbssna/provide-fournir/pharma-prod/med-list/04-00-eng.php>
- Herridge CF, A'Brook MF. 1968. Ephedrine psychosis. *British Medical Journal* 2:160.
- Hutchins GM. 2001. Correspondence: Dietary supplements containing ephedra alkaloids. *The New England Journal of Medicine* 344(14):1094-1100.
- IOM 2002: Institute of Medicine. 2002. *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids*. Washington (DC): The National Academy of Sciences.



- Jacobs KM, Hirsch KA. 2000. Psychiatric complications of Ma-Huang. *Psychosomatics* 41(1):58-62.
- Katz JL. 2000. A psychotic manic state induced by an herbal preparation. *Psychosomatics* 41(1):73.
- Kim HK, Choi YH, Chang WT, Verpoorte R. 2003. Quantitative analysis of ephedrine analogues from ephedra species using ¹H-NMR. *Chemical & Pharmaceutical bulletin* 51(12):1382-1385.
- Kitani Y, Zhu S, Omote T, Tanaka K, Batkhuu J, Sanchir C, Fushimi H, Mikage M, Komatsu K. 2009. Molecular analysis and chemical evaluation of ephedra plants in Mongolia. *Biological & Pharmaceutical Bulletin* 32 (7):1235-1243.
- Laitinen LA, Empey DW, Bye C, Britton MG, McDonnell K, Hughes DTD. 1982. A comparison of the bronchodilator action of pseudoephedrine and ephedrine in patients with reversible airway obstruction. *European Journal of Clinical Pharmacology* 23:107-109.
- Lake CR, Tenglinet R, Chernow B, Holloway, H. 1983. Psychomotor stimulant-induced mania in a genetically predisposed patient: a review of the literature and report of a case. *Journal of Clinical Psychopharmacology* 3(2):97-100.
- Lambert MT. 1987. Paranoid psychoses after abuse of proprietary cold remedies. *British Journal of Psychiatry* 151:548-550.
- Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. 2005. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. *American Journal of Psychiatry* 62(1):189-191.
- McGuffin M, Kartesz JT, Leung AY, Tucker AO, editors. 2000. *Herbs of Commerce*, 2nd edition. Silver Spring (MD): American Herbal Products Association.
- MHRA 2005: Medicines and Healthcare products Regulatory Agency. *The Medicines (Retail Sale or Supply of Herbal Remedies) Order 1977; S.I. 1977/2130 (UK)*. [Accessed 2018 June 1]. Available from: <http://www.legislation.gov.uk/uksi/1977/2130/made>
- MHRA 2009: MHRA Public Assessment Report - Controlling the risk of misuse of medicines containing pseudoephedrine and ephedrine. 2009. London (UK): Medicines and Healthcare products Regulatory Agency.
- Miller SC, Waite C. 2003. Ephedrine-type alkaloid-containing dietary supplements and substance dependence. *Psychosomatics* 44(6):508-511.
- Mills S, Bone K. 2000. *Principles and Practice of Phytotherapy*. Toronto (ON): Churchill Livingstone.



- Mizoguchi H, Wilson A, Jerdack GR, Hull JD, Goodale M, Grender JM, Tyler BA. 2007. Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. *International Journal of Clinical Pharmacology and Therapeutics* 45(4):230-236.
- Munns GF, Aldrich CA. 1927. Ephedrine in the treatment of bronchial asthma in children. *Journal of the American Medical Association* 88(16):1233.
- Nadir A, Agrawal S, King PD, Marshall JB. 1996. Acute hepatitis associated with the use of a Chinese herbal product, Ma-huang. *American Journal of Gastroenterology* 91(7):1436-1438.
- NAPRA 2009: Outline of National Drug Schedules. Search: ephedr [online]. Ottawa (ON): National Association of Pharmacy Regulatory Authorities. [Accessed 2009 December 17]. Available from: <http://napra.ca/pages/Schedules/Search.aspx>
- NHP 2009: Natural Health Products Ingredients Database. Ingredient Search: ephed [online]. Ottawa (ON): Natural Health Products Directorate, Health Canada. [Accessed 2009 November 27]. Available from: <http://webprod.hc-sc.gc.ca/nhpid-bdipsn/ingredsReq.do?srchRchTxt=ephed&srchRchRole=-1&lang=eng>
- Ranieri TL, Ciolino LA. 2008. Rapid selective screening and determination of ephedrine alkaloids using GC-MS footnote mark. *Phytochemical Analysis* 19:127-135.
- Rowe DJ, Baker AC. 2009. Perioperative risks and benefits of herbal supplements in aesthetic surgery. *Aesthetic Surgery Journal* 29(2):150-157.
- Sagara K, Oshima T, Misaki T. 1983. A simultaneous determination of norephedrine, pseudoephedrine, ephedrine and methylephedrine in Ephedrae Herba and oriental pharmaceutical preparations by ion-pair high-performance liquid chromatography. *Chemical & Pharmaceutical Bulletin (Tokyo)* 31(7):2359-2365.
- Samenuk D, Link MS, Homoud MK, Contreras R, Theoharides TC, Wang PJ, Estes III NAM. 2002. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. *Mayo Clinic Proceedings* 77:12-16.
- Slodki SJ, Montgomery CA. 1965. Clinical comparison of oxymetazoline and ephedrine in nasal congestion. *Current Therapeutic Research, Clinical and Experimental* 7:19-22.
- Song HJ, Shim KN, Ryu KH, Kim TH, Jung SA, Yoo K. 2008. A case of ischemic colitis associated with the herbal food supplement ma huang. *Yonsei Medical Journal* 49(3):496-499.
- TGA 2008: Australian Therapeutic Goods Administration. Personal Import Scheme for Unapproved Medicines [online]. Symonston (AU): Australian Government Department of Health and Ageing, Therapeutic Goods Administration. [Accessed 2009 November 23]. Available from: <http://www.tga.gov.au/import/persimp.htm>



Theoharides TC. 1997. Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink. *Journal of Clinical Psychopharmacology* 17(5):437-439.

UMC 1997: Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. *ADRAC Bulletin*, Vol 16, No 4, November 1997. [Accessed 2009 November 20] Available from: <http://www.who-umc.org/DynPage.aspx?id=14325>

US FDA 1993: United States Food and Drug Administration. Cold, Cough, Allergy, Bronchodilator and Antiasthmatic Drug Products for Over-the-Counter Human Use; Amendment of Final Monograph for OTC Bronchodilator Drug Products [online]. *Federal Register*, Volume 58, Number 201, October 20, 1993, Final Rule. Docket Number 91N-0323. Rockville (MD): Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2009 November 23]. Available from: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm116064.pdf>

US FDA 1997: United States Food and Drug Administration. Dietary Supplements Containing Ephedrine Alkaloids [online]. *Federal Register*, Volume 62, Number 107, June 4, 1997, Proposed Rule. Docket Number 95N-0304. Rockville (MD): Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2009 November 23]. Available from: <http://frwebgate1.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=999886443355+0+1+0&WAIAction=retrieve>

Vahedi K, Domigo V, Amarenco P, Bousser MG. 2000. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. *Journal of Neurology, Neurosurgery, and Psychiatry* 68:112-113.

Walton R, Manos GH. 2003. Psychosis related to ephedra-containing herbal supplement use. *Southern Medical Journal* 96(7):718-720.

White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. 1997. Pharmacokinetics and cardiovascular effects of ma huang (*Ephedra sinica*) in normotensive adults. *The Journal of Clinical Pharmacology* 37:116-122.

Whitfield AGW, Arnott WM, Waterhouse JAH. 1950. The effect of ephedrine in asthma and emphysema. *Quarterly Journal of Medicine* 19(76):319-326.

Whitehouse AM, Duncan JM. 1987. Ephedrine psychosis rediscovered. *British Journal of Psychiatry* 150:258-261.

Wingert WE, Mundy LA, Collins GL, Chmara ES. 2007. Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children. *Journal of Forensic Science* 52(2):487-490.

Zahn K, Li R, Purssell R. 1999. Cardiovascular toxicity after ingestion of "herbal ecstasy." *The Journal of Emergency Medicine* 17 (2):289-291.